Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1953848 | 0.91 | GAA (0.58) | GAAABL1TSHRMEN1KMT2A | |
| SCHEMBL11222239 | 0.88 | GAA (0.51) | GAAPOLBABL1TSHRMEN1 | |
| SCHEMBL828778 | 0.87 | CA12 (0.47) | GAAPOLBABL1TSHRLMNA | |
| SCHEMBL337450 | 0.87 | CA12 (0.47) | GAAPOLBABL1TSHRLMNA | |
| SCHEMBL25515986 | 0.87 | CA12 (0.47) | GAAPOLBABL1TSHRLMNA | |
| SCHEMBL829544 | 0.87 | CA12 (0.47) | GAAPOLBABL1TSHRLMNA | |
| SCHEMBL29869709 | 0.87 | CA12 (0.47) | GAAPOLBABL1TSHRLMNA | |
| SCHEMBL10616295 | 0.87 | CA12 (0.47) | GAAPOLBABL1TSHRLMNA | |
| Hydrochloric Acid SCHEMBL6380287 | 0.85 | CA12 (0.45) | GAAPOLBABL1TSHRLMNA | |
| SCHEMBL852553 | 0.83 | GAA (0.51) | GAAABL1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | disclosed |
| US-12415785-B2 | Compound modulators of sting | CTXT PTY LTD (AU) | 2025-09-16 | — | — | US | disclosed |
| CN-114981265-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | disclosed |
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | disclosed |
| WO-2022266711-A1 | SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS | Aculeus Therapeutics Pty Ltd (AU) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022266711-A1 | SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS | Aculeus Therapeutics Pty Ltd (AU) | 2022-12-29 | — | — | WO | disclosed |
| EP-4077318-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2022-10-26 | — | — | EP | disclosed |
| CN-114981265-A | Compound (I) | CTXT私人有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20050043310-A1 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
| WO-2004089897-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
| US-5750545-A | EXHIBIT EOSINOPHIL-INHIBITORY ACTION AND LYMPHOCYTE ACTIVATION-INHIBITORY ACTION; USEFUL FOR TREATMENT OF IMMUNE-RELATED DISEASES | THE GREEN CROSS CORPORATION (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0825187-A1 | Condensed pyridazinyl guanidines, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-25 | — | — | EP | disclosed |
| EP-0710654-A1 | TRIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-5175164-A | Hypotensive agents | MERCK & CO., INC. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0517357-A1 | Angiotensin II antagonists incorporating a substituted indole or dihydroindole | MERCK & CO. INC. (US) | 1992-12-09 | — | — | EP | disclosed |
| EP-0508723-A1 | Angiotensin II antagonists incorporating an indole or dihydroindole | MERCK & CO. INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| US-5151435-A | Hypotensive agents, glaucoma and cognition activators | MERCK & CO., INC. (US) | 1992-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043310-A1 | Preparation of quinoxaline compounds | CCKAR, CCKBR, GIPR | GAA 1615/4885POLB 3802/4885ABL1 1011/4885 |
| US-12415785-B2 | Compound modulators of sting | STING1, IRF3, MAVS | GAA 572/4885POLB 1735/4885ABL1 2874/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | GAA 2456/4885POLB 1166/4885ABL1 2303/4885 |
| US-20050038032-A1 | Quinoxaline compounds | CCKAR, CCKBR, GIPR | GAA 1879/4885POLB 4318/4885ABL1 763/4885 |
| US-20230062932-A1 | COMPOUNDS | STING1, IRF3, MAVS | GAA 337/4885POLB 1666/4885ABL1 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.